Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases

Abstract

A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; 'a' is a single bond; or 'a' is a double bond and one of Rand R, and one of Rand Rare absent; Ris H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO-alkyl, CORand an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from Rand R; Ris H, R, or an alkyl group optionally substituted with one or more Rgroups; R, R, R, and Rare each independently selected from H, R, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more Rgroups; or Rand R, and/or Rand Rtogether represent ═O; Ris H, R, NH(CH)R, CO(CH)R, NHCO(CH)R, O(CH)R, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from Rand R; Ris OR, NRR, halogen, CF, NO, COR, CN, COOR, CONRR, SORor SONRR; Ris a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more Rgroups; R, R, Rand Rare each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.